The role of the Cytogenetic Core Component (CCC) is to provide dedicated, prompt service to all investigators involved in the Hematology/BMT program project grant (PPG) by providing standardized classic cytogenetics, molecular cytogenetics (FSH), and RT-PCR services. The CCC's service goals are to provide the necessary genetic testing in order to estimate the frequencies and prognostic significance of cytogenetic abnormalities in marrow or blood cells prior to therapy and at various times during their course of treatment, to provide FSH technology, training and resources for the clinical and gene therapy projects (gene integration/localization), to provide bcr-abl RT-PCR testing, and to provide quality control for all cytogenetic-based testing involved in this program project (Projects I, II, VI, and VIII). In addition, the CCC will function as a reference laboratory for the collaborative studies involving the Southwest Oncology Group (SWOG, Project I), Stanford University (Projects I, II), Cancer Center of British Columbia, University of California and Alta Bates (Project II). Dr. Slovak will serve as the Cytogenetic Study Co-ordinator for SWOG-9400 (Project I). All technical aspects of cancer cytogenetics (classic and molecular) and PCR technology are currently in place. The cytogenetic data will be maintained on our computerized ACLAIMS cytogenetic information management system (W-Technology, Sacramento, CA). Cytogenetic data is readily accessible to all project leaders through a customized, search program and easily transferable to the Biostatistics Core. This centralized facility will ensure high quality, standardized service without duplication of effort in a timely manner.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA030206-18
Application #
6102101
Study Section
Project Start
1999-02-01
Project End
2000-03-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
18
Fiscal Year
1999
Total Cost
Indirect Cost
Name
City of Hope National Medical Center
Department
Type
DUNS #
City
Duarte
State
CA
Country
United States
Zip Code
91010
Limaye, Ajit P; La Rosa, Corinna; Longmate, Jeff et al. (2016) Plasma IL-10 Levels to Guide Antiviral Prophylaxis Prevention of Late-Onset Cytomegalovirus Disease, in High Risk Solid Kidney and Liver Transplant Recipients. Transplantation 100:210-6
Mardiros, Armen; Forman, Stephen J; Budde, Lihua E (2015) T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia. Curr Opin Hematol 22:484-8
Caruso, Hillary G; Hurton, Lenka V; Najjar, Amer et al. (2015) Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity. Cancer Res 75:3505-18
Israyelyan, A; Goldstein, L; Tsai, W et al. (2015) Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantation. Bone Marrow Transplant 50:26-33
Jonnalagadda, Mahesh; Mardiros, Armen; Urak, Ryan et al. (2015) Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy. Mol Ther 23:757-68
Wang, Xiuli; Wong, ChingLam W; Urak, Ryan et al. (2015) CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells. Clin Cancer Res 21:2993-3002
Wussow, Felix; Chiuppesi, Flavia; Martinez, Joy et al. (2014) Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complex. PLoS Pathog 10:e1004524
Rushworth, David; Jena, Bipulendu; Olivares, Simon et al. (2014) Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric antigen receptor independent of specificity. J Immunother 37:204-13
Jena, Bipulendu; Moyes, Judy S; Huls, Helen et al. (2014) Driving CAR-based T-cell therapy to success. Curr Hematol Malig Rep 9:50-6
Singh, Harjeet; Huls, Helen; Kebriaei, Partow et al. (2014) A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19. Immunol Rev 257:181-90

Showing the most recent 10 out of 364 publications